Once-Daily Tiotropium Respimat® Add-on to at Least Ics Maintenance Therapy Demonstrates Improved Lung Function in Patients with Symptomatic Asthma, Independent of Serum IgE or Blood Eosinophil Levels

Once-Daily Tiotropium Respimat® Add-on to at Least Ics Maintenance Therapy Demonstrates Improved Lung Function in Patients with Symptomatic Asthma, Independent of Serum IgE or Blood Eosinophil Levels

Rationale In adults with moderate or severe symptomatic asthma, once-daily tiotropium Respimat® add-on to at least ICS maintenance therapy has demonstrated lung-function improvements in conventional subgroup analyses, independent of serum IgE 430μg/L (equivalent to 179.2 IU/L) and blood eosinophil...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 2016-02, Vol.137 (2), p.AB213-AB213
Hauptverfasser: Tashkin, Donald P, Dahl, Ronald, MD, Virchow, Johann Christian, MD, Engel, Michael, MD, Moroni-Zentgraf, Petra, MD, Zaremba-Pechmann, Liliana, PhD, Kerstjens, Huib A.M., MD
Format: Artikel
Sprache:eng
Schlagworte:
Allergy and Immunology
Asthma
FDA approval
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Rationale In adults with moderate or severe symptomatic asthma, once-daily tiotropium Respimat® add-on to at least ICS maintenance therapy has demonstrated lung-function improvements in conventional subgroup analyses, independent of serum IgE 430μg/L (equivalent to 179.2 IU/L) and blood eosinophils 0.6x109/L (equivalent to 600/μL).
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2015.12.1283